Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice

BACKGROUND: To evaluate the change in best corrected visual acuity (VA) and central macular thickness (CMT) following treatment with intravitreal aflibercept (AFL) in patients poorly responders or non responders to ranibizumab (RBZ). METHODS: Charts of patients injected with RBZ from January 2016 to...

Descripción completa

Detalles Bibliográficos
Autores principales: de Sá Quirino-Makarczyk, Luciana, Sainz Ugarte, Maria de Fátima, Viana Vieira, Bruna, Kniggendorf, Sérgio, Saito Regatieri, Caio Vinicius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222566/
https://www.ncbi.nlm.nih.gov/pubmed/32467776
http://dx.doi.org/10.1186/s40942-020-00212-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222566/
https://www.ncbi.nlm.nih.gov/pubmed/32467776
http://dx.doi.org/10.1186/s40942-020-00212-5

Ejemplares similares